2-Amino-3-chloropyridine → 8-Chloro-2-(5-methyl-3-phenyl-isoxazol-4-yl)-imidazo[1,2-a]pyridine
Reaktionsgleichung
Br[CH2:2][C:3]([C:5]1[C:6]([C:11]2[CH:16]=[CH:15][CH:14]=[CH:13][CH:12]=2)=[N:7][O:8][C:9]=1[CH3:10])=O.[NH2:17][C:18]1[C:23]([Cl:24])=[CH:22][CH:21]=[CH:20][N:19]=1>>[Cl:24][C:23]1[C:18]2[N:19]([CH:2]=[C:3]([C:5]3[C:6]([C:11]4[CH:16]=[CH:15][CH:14]=[CH:13][CH:12]=4)=[N:7][O:8][C:9]=3[CH3:10])[N:17]=2)[CH:20]=[CH:21][CH:22]=1Komponenten
3
Versuchsvorschrift
As described for Example 1, 4-(bromoacetyl)-5-methyl-3-phenylisoxazole (commercially available) (140 mg, 0.5 mmol) was converted, using 2-amino-3-chloropyridine instead of 2-aminopyridine, to the title compound (117 mg, 76%) which was obtained as a yellow foam. MS: m/e=310.3 [M+H]+.
Quellen und Nachweise
- ORD-Eintrag
- ord-db797744b7914162b3c265ff30353a5b
- Quelldatensatz
- uspto-grants-2009_09
- DOI